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Background: The National Cancer Institute (NCI) has supported implementation science for over a decade. We
explore the application of implementation science across the cancer control continuum, including prevention,
screening, treatment, and survivorship.
Methods: We reviewed funding trends of implementation science grants funded by the NCI between 2000 and
2012. We assessed study characteristics including cancer topic, position on the T2–T4 translational continuum,
intended use of frameworks, study design, settings, methods, and replication and cost considerations.
Results: We identified 67 NCI grant awards having an implementation science focus. R01 was the most common
mechanism, and the total number of all awards increased from four in 2003 to 15 in 2012. Prevention grants were
most frequent (49.3%) and cancer treatment least common (4.5%). Diffusion of Innovations and Reach, Effectiveness,
Adoption, Implementation, Maintenance (RE-AIM) were the most widely reported frameworks, but it is unclear how
implementation science models informed planned study measures. Most grants (69%) included mixed methods,
and half reported replication and cost considerations (49.3%).
Conclusions: Implementation science in cancer research is active and diverse but could be enhanced by greater
focus on measures development, assessment of how conceptual frameworks and their constructs lead to improved
dissemination and implementation outcomes, and harmonization of measures that are valid, reliable, and practical
across multiple settings.
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The National Cancer Institute (NCI) has long supported
innovative cancer prevention and control research that
has produced numerous efficacious interventions for
improving cancer screening, tobacco cessation, and
promoting nutrition, physical activity, and sun safety
[1]. However, traditional generation and evaluation of
evidence in cancer control is often slow, costly, or
insufficiently generalizable to provide decision-makers
with useful, effective strategies for cancer control in
clinical, community, and policy settings [2]. Inadequate
attention to the implementation process has resulted in* Correspondence: netagil@mail.nih.gov
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unless otherwise stated.an enormous gap between evidence generated and
actions taken to implement such evidence into routine
clinical and public health practice [3]. Therefore, the
usefulness of efficacious interventions developed under
highly controlled research conditions has been under-
mined by the difficulties to translate them into complex,
real-world settings. Implementation science is vital to
reach the ultimate goal of improving research impact to
improve cancer outcomes in the broader population,
thereby achieving a return on scientific investment. While
there are several definitions for implementation science,
Eccles and Mittman define implementation science as
“the scientific study of methods to promote the systematic
uptake of research findings and other evidence-basedhis is an Open Access article distributed under the terms of the Creative
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iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Neta et al. Implementation Science  (2015) 10:4 Page 2 of 10practices into routine practice, and, hence, to improve the
quality and effectiveness of health services and care [4].”
To bridge the discovery-to-delivery gap, the National
Institutes of Health (NIH) has made translational science
a research priority. In 2006, NIH launched the Clinical and
Translational Science Awards (CTSA) and other funding
programs to address the development and implementation
of national standards, best practices, and infrastructure
support for translational research [5-7]. Within the CTSA
announcement, translational science defines two areas of
translational research: 1) “the process of applying discov-
eries generated during research in the laboratory, and
in preclinical studies, to the development of trials and
studies in humans”, and 2) “research aimed at enhancing
the adoption of best practices in the community [8].”
Despite both areas falling under the same translational
research heading, the two stages of research require
different methods, measures, and outcomes; the first
utilizes methods to move from fundamental biology to
clinical application, while the second requires methods
to map the complexity of clinical and community settings
to identify the optimal fit of research within these real-
world contexts. Studies of dissemination (i.e., actively
spreading evidence-based interventions (EBIs) to the
target audience via determined channels using planned
strategies) and implementation (i.e., putting to use or
integrating evidence-based interventions within a setting)
fall within this second translational research area, often
referred to as implementation science [9]. Implementation
science emerged as a response to these distinct scientific
needs to formulate strategies for promoting adoption of
EBIs into clinical and public health practice, effectively
reaching targeted populations, and understanding imple-
mentation processes across settings. Studying such strat-
egies can yield important research findings that can be
applied in routine care to improve cancer outcomes.
The NCI has been active in developing and promoting
research grant opportunities as well as training institutes
and workshops and providing institutional support for
implementation science. The NCI’s support for this
research field, also referred to as dissemination and imple-
mentation (D&I) research, began through administrative
supplements funded from 2001 to 2008. Initially, sup-
plements supported dissemination and implementation
research of behavioral interventions. In 2006, the NCI ex-
panded the scope of D&I research supplements to include
D&I of surveillance research. During this 7-year period,
the NCI successfully awarded 20 1-year, non-competitive
administrative supplements of approximately $100,000 to
$220,000, total costs, to investigators with active parent
research project grants (R01s), research program project
grants (P01s), and research project cooperative agree-
ments (U01s) [10]. The supplement program’s success led
to the NCI’s co-sponsoring the initial Trans-NIH ProgramAnnouncements on D&I Research in Health (DIRH PAR)
in 2006 with eight other institutes and centers. Currently,
16 institutes and centers participate in the trans-NIH
funding announcement and they have awarded 116 re-
search grants between 2006 and 2013. Additionally, NIH
has supported seven annual conferences focused on D&I
and ten annual week-long trainings on D&I Research in
Health [11,12]. Funding opportunities and trainings have
contributed to the tremendous growth of implementation
science literature in peer-reviewed journals such as Imple-
mentation Science and Translational Behavioral Medicine.
While interest in implementation science has grown, the
field is still an emerging and evolving discipline.
Through this period of growth, the field of implemen-
tation science has largely moved from a set of studies
chronicling the many barriers and facilitators to success-
ful adoption, uptake, and sustainability, to one focused
on designing strategies to improve the transportation of
EBPs into a myriad of settings. The past decade has seen
movement toward the comparison of implementation
strategies [13] to “implementation as usual” and more
recently to the comparison of multiple active strategies.
Simultaneously, researchers have been advancing the
methods and measures of implementation science [14],
working to increase the rigor and robustness of these
complex processes.
Given the rapid growth and interest in the field of
implementation science across the NIH, a review of the
NCI extramural grant portfolio is timely. The purpose of
this paper is to a) describe the funding characteristics
and trends in implementation science supported by the
NCI between 2000 and 2012, b) summarize study char-
acteristics of implementation science funded by the NCI
during that period, and c) discuss current implementa-
tion science needs and future opportunities to improve
cancer prevention and control outcomes. This review
identifies scientific gaps in the NCI extramural grant
portfolio and encourages research needed to advance the
field of implementation science.
Methods
We searched for grants awarded between fiscal years
2000 and 2012 using an internal NCI extramural database,
Portfolio Management Application (PMA), to identify
NCI-funded implementation science grants. Given there
are no codes to identify implementation science within
PMA, we used a text search to identify NCI grants in this
area. To guide selection of search terms, we adopted the
NIH definition of dissemination as “the targeted distribu-
tion of information and intervention materials to a specific
public health or clinical practice audience” and implemen-
tation as “the use of strategies to adopt and integrate
evidence-based health interventions and change practice
patterns within specific settings” [6]. Our search query
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research projects related to implementation science.
This query included abstracts and titles of all awarded
NCI grants and competing supplements using multiple
combinations of the following terms: dissemination,
implementation, diffusion, pragmatic research, translation
research, and translational research. Any duplicative
grants were removed. An NCI staff member compiled
and reviewed project abstracts from the initial search
results to determine potential relevance to implementation
science. A second NCI staff member reviewed a random
10% sample of all abstracts for quality control. Because
information on individual non-competing administrative
supplement awards is scarcely available within the NCI
extramural databases, these awards were not included
in our review. Additional analysis of a subset of non-
competing implementation science administrative sup-
plements are available elsewhere [15].
Eight NCI Implementation Science team members
piloted a coding process on three implementation science
grant applications not included in this analysis to establish
reviewer consensus on coding criteria. Full applications
for all grant awards identified as potentially relevant were
reviewed by NCI team members with expertise in IS
and extramural grants. The eight members participated
in the content review and were randomly paired to
assess applications. Once paired, reviewers independently
assessed the full grant application including specific aims,
methodology, and intended outcomes to determine inclu-
sion or exclusion from the analysis. To be included in our
analysis, the awards had to focus on topics within the
cancer control continuum [16], have either a dissemin-
ation or implementation research objective, and involve
human subjects. Applications were excluded if they were
administratively focused (e.g., solely capacity building)
and/or did not meet at least one of the following criteria:
a) involve a human component, b) focus on cancer control
continuum topics, or c) have either a dissemination or im-
plementation research objective. All exclusions were based
on the consensus of the paired reviewers. If there was no
consensus, a third person (M.A.S.) reviewed the grant and
final exclusion decisions were negotiated.
Included research projects were coded by paired re-
viewers working independently on the same data. Clear
guidelines and codebook were developed by the authors
so codes could be applied consistently to several categories
including cancer prevention and control topic areas (e.g.,
breast cancer screening, diet/nutrition, informed decision-
making, public health genomics, treatment), stated imple-
mentation science objectives (e.g., dissemination: an active
approach of spreading EBIs to the target audience via
determined channels using planned strategies; adoption:
the decision of an organization or a community to commit
to and initiate an EBI; implementation: the process ofputting to use or integrating EBIs within a setting; sus-
tainability: extent to which an EBI can deliver intended
benefits over an extended period of time after external
support from the donor agency is terminated) [9], transla-
tion research phase T2–T4 (T2 = efficacy studies, T3 = ef-
fectiveness studies, T4 = public health outcome studies)
[6], study design (e.g., randomized control trial, group ran-
domized trial, simulation), setting (e.g., community, faith
based, home based), sustainability considerations (e.g.,
capacity building, cost analysis), replication indicators
(e.g., monetary and/or non-monetary costs), use of imple-
mentation science frameworks or models (e.g., diffusion of
innovation, Reach, Effectiveness, Adoption, Implemen-
tation, Maintenance (RE-AIM), Chronic Care Model),
and analytic methods (e.g., qualitative, quantitative, cost-
effectiveness). Multiple coding assignments within classifi-
cation categories were allowed within each award. For
example, an award could be coded for both qualitative
and quantitative analytic methods. For center grants (P50s),
only the implementation science component of the grant
was classified by the aforementioned categories. All coding
information for each grant award was collected via Survey-
Monkey and extracted into Stata 12.0 for data cleaning and
analysis. We provide descriptive statistics on both study
and funding characteristics and describe trends over time.
Results
A total of 968 grants were retrieved from our combined
query search. We removed all duplicative or ineligible
grant awards, leaving 323 potentially relevant awards. Of
the 323 awards, 111 were determined relevant to imple-
mentation science. Primary reasons for exclusion included
1) no stated dissemination or implementation research
objective or 2) the implementation science component
was administratively focused (i.e., infrastructure develop-
ment or capacity building to conduct research). After full
review, 67 grant awards were deemed implementation
science relevant for our analysis (Figure 1).
The majority (70%) of included awards were large
research project grants (R01s—up to 5 years of funding
for discrete research project). Fifteen were small or devel-
opmental research projects (R03s, R21s—up to 2 years
of funding for developmental, feasibility or pilot study),
three were center grants (P50s—for large, multi-project
specialized centers), one was a cooperative agreement
(U01—similar to R01 but with substantial programmatic
involvement from the funding agency), and one was a
small business innovation research grant (R43 to stimulate
technological innovation in the private sector). No com-
petitive supplements were found to be implementation
science relevant for our analysis largely because these were
focused on dissemination or implementation activities and
not research per se. Fewer than half (43%) of the imple-
mentation science grant awards funded between 2000 and
Figure 1 Schematic summary of the selection process used in the portfolio analysis grant review.
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Program Announcements (DIRH PAR) [7,17,18] (Table 1).
Of these, the majority (69%) were R01 research projects.
The remaining grants funded through the DIRH PAR
were small or developmental research grants, including
R21s (28%) and R03s (3%). Similarly, of those grants
awarded outside of the DIRH PAR, the majority (71%) were
R01 research projects, which included nine investigator-
initiated grants (awarded before 2009), eight grants sub-
mitted under the parent R01 (from 2009 to 2012), and 10
grants in response to specific program announcements.
The DIRH PAR success rate for new and competing
grants between FY 2000 and FY 2012 was 24.3% whereas
the success rate for new and competing grants during the
same time period for NCI cancer prevention grants
(funded by the NCI’s Division of Cancer Control and
Population Sciences) as a whole was 20.2% (including only
R01s, R21s, and R03s, the only three mechanisms granted
under the DIRH PAR.) While this is a small difference,looking only at R01s, the difference is greater: 26.7% (for
DIRH) to 19.1% (NCI as a whole). Success rates for R03s
and R21s are comparable between the two groups (15%
for R21s, ~30% for R03s).
Only three awardees were new investigators, all of
whom were funded through the DIRH PAR. The pro-
portion of new investigator awards during the period
FY 2000–2012 at NCI as a whole was 24.2% whereas
for the DIRH PAR alone, it was 43.8%. This includes all
awarded, pending and to be paid new and competing
R01 grants. If restricting to awarded grants only, the
proportions are 20% and 25%, respectively. Over a
quarter (28%) of the 67 total NCI-funded grants came
from four institutions: University of Washington St.
Louis (n = 7), Dana Farber Cancer Institute (n = 4), Kaiser
Foundation Research Institute (n = 4), and University
of North Carolina Chapel Hill (n = 4), three of which
were Cancer Prevention and Control Research Net-
work (CPCRN) grantees. The CPCRN is co-funded by
Table 1 NCI-funded implementation science awards by program announcement and grant mechanism, fiscal years
2000-2012
Announcement Mechanism Funds Number of awards (%) Average cost per grant Average cost per grant per year
DIRH PAR
R01 $25,157,077 20 (69) $1,257,854 $545,627
R21 $2,778,562 8 (28) $347,320 $187,859
R03 $150,000 1 (3) $150,000 $75,000
Totals $28,085,639 29
Other announcements
R01 $63,790,377 27 (82) $2,362,607 $564,723
R21 $952,411 4 (12) $238,103 $119,051
R03 $300,500 2 (6) $150,250 $75,125
Totals $65,043,288 33
Overall
R01 $88,947,454 47 (76) $1,892,499 $556,597
R21 $3,730,973 12 (19) $310,914 $164,923
R03 $450,500 3 (5) $150,167 $75,083
Totals $93,128,927 62
Funding for projects recently awarded in 2013 are not included.
DIRH PAR Dissemination and Implementation Research in Health Program Announcement.
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collaborations.
The NCI awarded approximately $89 million in total
costs toward implementation science through the R01
mechanism, averaging $557,000 per grant per year. Dur-
ing the same time period, exploratory research grants
(R21) funded $3.7 million in total costs, averaging
$165,000 per grant per year, while the small grant pro-
gram (R03) received $450,500 in total costs, averaging
$75,000 per grant per year (Table 1). The number of
NCI-funded implementation science grants has nearly
quadrupled in the last decade from four in 2003 to 15 inFigure 2 Trends in NCI-funded grants in implementation science by f
awarded in implementation science funded by the National Cancer Institut
Implementation Research in Health Program Announcement versus all oth2012 (Figure 2), with peaks in 2006, 2009, and 2011/
2012. However, the DIRH PAR was not always the primary
funding announcement supporting IS over this time
period. NCI funding for implementation science consist-
ently increased for R01 research projects from $1.9 million
in 2003 to $15.1 million in 2012, while R03 and R21
awards remained relatively flat between 2006 and 2012
(Figure 3). To our knowledge, no implementation science
relevant grants were funded by NCI between 2000 and
2002.
A wide range of implementation science has been funded
by the NCI, spanning the cancer control continuum andunding announcements, fiscal years 2000–2012. Trends in grants
e (NCI), fiscal years 2000–2012, overall and for the Dissemination and
er NCI funding announcements.
Figure 3 Funding trends of NCI-funded implementation science by grant mechanism, fiscal years 2000–2012. Funding trends of
implementation science by grant mechanism (R01, R21, R03) funded by the National Cancer Institute, fiscal years 2000–2012.
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(Table 2). The majority of grant awards addressed cancer
prevention (49%) or screening (40%), with fewer studies
examining cancer treatment (4%) and survivorship (6%).
Cross-cutting applications addressed cancer surveillance,
information services, and EBIs broadly defined. The most
common topic area of awarded grants was tobacco control
(39%), followed by colorectal cancer (30%), breast cancer
(18%), and cervical cancer screening (12%). Regarding core
implementation science objectives, just under half of the
grants (46%) addressed dissemination research objectives
and less than a third (30%), adoption. Most awards (79%)
included an implementation component. Although sus-
tainability was a stated objective in 26 awards (39%), 39
awards (58%) included at least one sustainability consider-
ation, such as capacity building (30%), intervention main-
tenance (37%), or cost analysis (22%).
The vast majority (91%) of awards were classified as T3
studies. Only eight awards (12%) were classified as T4
studies, half of which were cross-classified as T3. Eight
awards (12%) were classified as T2 studies, six of which
were cross-classified as T3. The most common study
setting was clinical (52%), followed by community (27%),
workplace (15%), online (10%), school based (9%), and
faith or home based (4.5% each). Collaborative processes
(i.e., including stakeholder engagement, community-based
participatory research, patient engagement, designing for
dissemination, and team science) were used in the vast
majority of awards (90%). The most common study design
proposed was the experimental, randomized controlled
trial (58%). Nearly one third (31%) of grant awards were
observational, and only a handful were experimental, non-
randomized trials (7%) or modeling studies (3%). Units of
analyses included both individual level (73%) and group
level (63%). The majority of grant awards planned to use
qualitative (81%) or quantitative (88%) methods, many ofwhich used both (69%). The most frequently named
conceptual frameworks were Diffusion of Innovations
(39%) and RE-AIM (34%). The majority of awards used
frameworks for intervention design (71.6%) and measured
variables (62.1%). Almost half of the awarded grants (48%)
incorporated more than one framework or used only one
framework (46%). Five awards did not use a framework.
All study characteristics are described in Table 2.
Discussion
The purpose of this paper is to describe the funding
characteristics and trends of implementation science
supported by the NCI between 2000 and 2012, summarize
characteristics of implementation science funded by the
NCI, and discuss current implementation science needs
and future opportunities that may improve cancer pre-
vention and control outcomes. Our review assessed 67
implementation science grant awards funded by the NCI
between fiscal years 2000 and 2012 across a variety of
cancer control topics, study designs and methods, and
translational phases of research demonstrating a diverse
set of research projects, reflecting a rapidly evolving area
of science. Our portfolio analysis revealed several interest-
ing findings. First, the number of NCI-awarded grants
supporting implementation science has increased tremen-
dously over a 10-year period in both number of grants
and total funding amount, largely through the R01 mech-
anism. This increase indicates the growing interest in
implementation science cancer control research and
the ability of investigators to successfully compete for
implementation science grant awards. We also noticed
continued success and growth in the number of awards
after the introduction of the DIRH PAR in 2006 and
again in 2009, when a standing study section in D&I
research replaced a special emphasis panel. Moreover, the
initiation of the annual Training Institute for Dissemination
Table 2 Number and percentage of NCI-funded
implementation science research grants by study
characteristics, fiscal years 2000-2012
Characteristic Number
of grantsa
Percent
of grantsa
Cancer control continuum
Prevention 33 49.3
Screening 27 40.3
Diagnosis 0 0.0
Treatment 3 4.5
Survivorship 4 6.0
Cross-cutting 7 10.4
Types of cancer/risk factors
Colorectal cancer 20 29.9
Breast cancer 12 17.9
Cervical cancer 8 11.9
Tobacco 26 38.8
Physical activity 6 9.0
Diet/nutrition 5 7.5
Sun safety 5 7.5
Public health genomics 4 6.0
Obesity 3 4.5
Implementation science objectives
Dissemination 31 46.3
Adoption 20 29.9
Implementation 53 79.1
Sustainability 26 38.8
Sustainability indicators
Capacity building 20 29.9
Maintenance 25 37.3
Cost analysis 15 22.4
Place on T2–T4 continuum
T2 (efficacy studies) 8 11.9
T3 (comparative effectiveness) 61 91.0
T4 (outcomes research) 8 11.9
Study settings
Community 18 26.9
Faith based 3 4.5
School based 6 9.0
Clinical 35 52.2
Workplace 10 14.9
Home based 3 4.5
Online 7 10.4
Collaborative processes
Yes 60 90
No 7 10
Table 2 Number and percentage of NCI-funded
implementation science research grants by study
characteristics, fiscal years 2000-2012 (Continued)
Study design
Experimental, randomized control trial 39 58.2
Experimental, nonrandomized trial 5 7.5
Observational 21 31.3
Modeling 2 3.0
Methods used
Qualitative 54 80.6
Quantitative 59 88.1
Comparative effectiveness 35 52.2
Cost analysis 18 26.9
Simulation models 2 3.0
Network analysis 1 1.5
Frameworks/models
RE-AIM 23 34.3
Diffusion of Innovation 26 38.8
Organizational Change 7 10.4
Systems/Network Theories 5 7.5
Chronic Care Models 7 10.4
Model of Diffusion in Service Organizations 3 4.5
How the model was used
Intervention design 48 71.6
Formative research 22 32.8
Measured variables 41 61.2
Only stated 5 7.5
Replication costs considerations
Yes 33 49.3
No 31 46.3
NA 3 4.5
aNumbers add up to more than 67 (100%) in some cases because a given
grant may fit into more than one category.
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contributed to further growth in the number of awards in
2011 and 2012, as it made available to the field a large col-
lection of implementation science lectures and tools.
However, the number of new investigators supported by
NCI grant awards in implementation science was dismally
low during this time period. These findings suggest limited
training opportunities available in academic programs for
implementation science topics. Recent NIH efforts are ad-
dressing this challenge by investing in training the next
generation of implementation science investigators [19].
Although current NIH-sponsored trainings do not meet
the demand and growing interest in this field, additional
training strategies, including webinars, graduate courses,
and continuing education programs, may support new
Neta et al. Implementation Science  (2015) 10:4 Page 8 of 10investigators [20]. We also found that small or develop-
mental research projects (i.e., R03s and R21s) were few
and remained relatively flat in funding over time. This
does not necessarily mean that the NCI is not supporting
R03s and R21s in implementation science. Rather, the
NCI could be receiving few applications using these mech-
anisms for implementation science. This is consistent with
what other NIH institutes and centers have reported in
terms of funding small developmental grants [21]; thus,
the NCI is not unique in this respect. Moreover, compar-
ing the success rates of R03s and R21s through the DIRH
PAR specifically compared with cancer prevention and
control grants in general, we found that the rates are com-
parable: success rates for R03s were 33.3% for DIRH, 30.2%
in general; and for R21s, 15.0% for DIRH, 15.3% in general.
Future applicants could use these mechanisms to focus on
developmental and observational studies, implementation
feasibility research, and development of measures that are
valid, reliable, and practical given the limited budget pro-
vided under these mechanisms [22-24]. In addition, as a
range of data sources have become available for mining by
researchers, retrospective analyses of implementation ef-
forts and simulation studies of potential approaches to im-
plement effective practices can be fostered [17,18].
Our review illustrates the breadth of implementation
science cancer control research spanning across 14 topic
areas, with tobacco control as the most common topic.
This finding may be reflective of the advanced state of
the science in policy and population-level intervention
research in tobacco control [25], making it more amen-
able to T3–T4 translational research. In contrast, fewer
studies focused on obesity, which is a more recent public
health problem compared with tobacco control, and
thus, fewer policies and evidence-based interventions
may exist. Similarly, studies on cancer prevention and
screening were more common than those of survivor-
ship, perhaps because of the numerous existing interven-
tions in cancer screening compared with those in cancer
survivorship. Based on the NCI-sponsored database of
Research-Tested Intervention Programs (RTIPS) (http://
rtips.cancer.gov/rtips/index.do), there are more than twice
as many evidence-based interventions in tobacco control
compared with obesity prevention and three times as many
in cancer screening compared with cancer survivorship.
We found diversity across study designs, methods, and
conceptual frameworks used. The majority of awards pro-
posed a randomized control trial design, with the unit of
analyses at both group and individual levels. It would be
interesting to assess how such trials balance rigor with
practical design features (i.e., pragmatic trial criteria), both
within the award and in publication of study results [26].
This balance reflects intervention feasibility and, if feasible,
increases the likelihood that they will be adopted by similar
settings. Pragmatic trials and accompanying tools leveragerigor and relevance to study effectiveness of interventions
in real-world settings. Such trials are commonly used in
implementation science to determine intervention effects,
for whom, and under what conditions [27,28].
We examined the composition of D&I research objectives
(i.e., dissemination, adoption, implementation, sustainabil-
ity) in our portfolio analysis. These objectives are distinct
concepts that make up parts of the continuum of imple-
mentation science. All of these concepts are important for
translating evidence into practice, so it is important to
understand which of these objectives are being studied in
the context of implementation science and which may be
lacking or under-evaluated. While most studies examined
implementation and roughly half, dissemination, less than a
third examined adoption. Adoption is distinct from imple-
mentation in that it assesses the degree to which relevant
organizations or settings decide to adopt an intervention
or program while implementation assesses the strategies
used to implement the intervention or program within
organizations or settings. Although only 38% examined
sustainability explicitly, we were encouraged to find that
about half of grant awards proposed cost indicators and/
or included replication considerations.
With this improved coverage across multiple stages of
implementation science, we see opportunities for cancer
control implementation science researchers to advance
key areas of under-representation in the field. Few studies
have examined the alternate to sustainability, that is, what
factors and strategies might influence rational attempts to
discontinue or de-implement cancer control interventions.
In addition, implementation science studies have rarely
attempted to implement multiple EBPs across the cancer
control continuum into a “braided” system of care. Finally,
we saw limited capture of the way in which interventions
adapt and evolve over time; a dynamic view of adoption,
implementation, and sustainability in future studies may
present a more naturalistic perspective on the fit of inter-
ventions within community and clinical contexts [29].
These and other priority questions highlighted in the
current PARs [7,17,18] remain as horizons for the field
and opportunities for subsequent investigation.
Almost all awards proposed both qualitative and quan-
titative methods. These are promising findings given that
the use of mixed methods is critical to adapt EBIs, under-
stand the context in which interventions are implemented,
and identify factors associated with successes and failures
of implementation efforts [30,31]. Unsurprisingly, Diffusion
of Innovations and RE-AIM—two of the more common
frameworks within the implementation science field—were
the most widely reported models in our sample. However,
most grant awards reported using more than one imple-
mentation science conceptual framework, and the primary
use of frameworks was for intervention design, while 39%
of studies did not use IS frameworks in dissemination or
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lem that very few frameworks offer construct measures
or empirical data supporting key variables necessary for
effective dissemination and implementation research,
despite the large number of implementation science
conceptual frameworks (over 61) [32]. Reliable, valid, and
pragmatic measures for theoretical constructs are urgently
needed to standardize measurement and advance imple-
mentation science systematically [20,23,24]. Several national
initiatives, including the NCI Grid-Enabled Measures Portal
[23,33], North Carolina Translational and Clinical Sciences
Institute [34], and Seattle Implementation Research Collab-
orative [35], are pooling available measures and seeking
consensus from the research community to harmonize
implementation science measurement.
Some study limitations warrant mention. Possibly, as
with any portfolio review, not all relevant grants were
identified and included in this review. To minimize the
likelihood that relevant grants were omitted, we used
multiple and broad search terms, multiple coders, and
clearly defined inclusion and exclusion criteria. We did
not include non-competitive supplemental awards in the
analysis as they are not available as independent items
within the PMA database. Additionally, the process for
ascertaining inclusion criteria and coding of grants re-
quired interpretation and judgment. We addressed these
issues by inter-rater consensus of any disagreements,
both for exclusion of full grant review and coding incon-
sistencies, but we did not measure nor report on coding
reliability. We also did not examine publications result-
ing from grant awards reviewed for this analysis. There-
fore, it is uncertain how much of the proposed research in
the awards was actually completed and whether changes
were made to study design post-funding. While this is a
comprehensive review, it is not an exhaustive review of all
cancer implementation science. Other foundations and
agencies fund similar projects. Also, we did not evaluate
the impact of implementation science awards. Despite
these limitations, we believe this analysis provides a
unique overall snapshot of implementation science funded
by the NCI.
Conclusion
Addressing the discovery-to-delivery gap and strategic-
ally investing limited national resources in translatable
health science has never been more critical. Our portfolio
analysis demonstrates growing interest in implementation
science in the context of cancer control and prevention
research. While we are encouraged by the number of
awarded grants across diverse topics, more focused and
systematic implementation science is needed to address
the field’s complex, multilevel, and interdisciplinary nature.
This includes systematic reviews of available implementa-
tion science measures, development of valid, reliable, andpractical measures, and empirical assessment of model
constructs relative to health outcomes. Additionally, our
portfolio analysis found very few grants focused on
exploratory research to address these gaps and few new
investigators were awarded implementation science grants.
Much work remains to systematically improve methods to
contribute significantly to cancer control research at the
NCI. We conclude that NCI-funded implementation
science in cancer control research is active and diverse but
could be enhanced by greater focus on measure develop-
ment, assessment of how conceptual frameworks and their
constructs lead to improved dissemination and implemen-
tation outcomes, and harmonized implementation science
measures that are valid, reliable, and practical across
multiple settings.
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